Study on Heart Disease Treatment Strategies

Introduction

A recent study aimed to explore various treatment strategies for heart disease, focusing on the most effective methods to minimize the risk of secondary cardiovascular problems.

Aspirin as a Treatment Option

Aspirin is frequently prescribed for heart disease management and has demonstrated its ability to lower the likelihood of recurrent cardiovascular incidents, including coronary artery disease, stroke, and arrhythmias. Furthermore, research indicates that aspirin may decrease the risk of specific cancer types by 19% and lower mortality rates associated with heart disease by 9%.

Vitamin K Inhibitors

Alternatively, many healthcare professionals suggest long-term treatment with vitamin K inhibitors, which are anticoagulants commonly referred to as blood thinners. These inhibitors may be utilized alone or in conjunction with aspirin and have shown superior efficacy compared to aspirin alone. However, due to the bleeding risks associated with vitamin K inhibitors, including potential intracranial hemorrhages, they are generally not advised for patients at risk of recurrent cardiovascular events.

Need for Alternative Treatments

This underscores the critical need for alternative treatment options to enhance the long-term survival of heart disease patients.

The COMPASS Trial

To identify a new treatment strategy, researchers from Canada initiated the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, spanning 33 countries. The trial aimed to evaluate whether rivaroxaban, either alone or in combination with aspirin, would be more effective and safer for heart disease patients than aspirin alone in reducing the risk of recurrent cardiovascular events.

Rivaroxaban Overview

Rivaroxaban is another anticoagulant typically utilized for treating deep vein thrombosis and preventing strokes. Previous studies have indicated that rivaroxaban can effectively lower the risk of cardiovascular death, stroke, and heart attacks in patients experiencing acute coronary syndrome.

Trial Methodology and Results

The findings of this double-blind randomized trial were recently published in The New England Journal of Medicine. A total of 27,395 participants with stable atherosclerotic vascular disease were randomly assigned to receive either rivaroxaban alone, rivaroxaban combined with aspirin, or aspirin alone. The primary outcome measured was a combination of cardiovascular death, stroke, or heart attack.

The results revealed that the combination of rivaroxaban and aspirin significantly outperformed aspirin alone, with a 24% reduction in the primary outcome rate. Although major bleeding events were more prevalent in the rivaroxaban plus aspirin group (with a 70% higher incidence), no significant difference was noted in instances of intracranial bleeding or fatal bleeding. Additionally, the combined treatment group experienced fewer deaths, with 313 fatalities compared to 378 in the aspirin-only group. Overall, the rivaroxaban plus aspirin group showed a 20% lower net clinical benefit than the aspirin-alone group, prompting an early termination of the trial due to the evident superior efficacy of this treatment.

Rivaroxaban Alone vs. Aspirin Alone

Patients receiving rivaroxaban alone did not display a significant reduction in the primary outcome, although a higher number of major bleeding events were recorded compared to the aspirin group.

Study Limitations and Implications

One limitation noted in the study is that early termination of trials due to observed superior efficacy can lead to an overestimation of treatment effectiveness. Nonetheless, prior to the trial’s conclusion, the safety board identified data indicating a progressive increase in benefits for patients treated with rivaroxaban and aspirin for over a year.

Conclusion

The comparison of the three treatment approaches for patients diagnosed with stable heart disease revealed that the combination of rivaroxaban and aspirin resulted in fewer adverse cardiovascular events. However, the risk of major bleeding was significantly higher in this group compared to those receiving only aspirin. The rivaroxaban-alone group did not show improved cardiovascular outcomes and had a greater risk of major bleeding than the aspirin-alone group. Thus, the study concluded that the optimal treatment for heart disease, providing the best net clinical benefit, is the combination of rivaroxaban and aspirin.

Author and Reference

Written by Lacey Hizartzidis, PhD
Reference: Eikelboom JW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118.